Avanos Medical Presents 2025 Estimates & Strategic Vision at JP Morgan Healthcare Conference
AVNS sits 23% above its 52-week low of $9.303.
Summary
Avanos Medical, Inc. presented its 2025 full-year estimates, strategic imperatives, and plans to mitigate significant tariff headwinds at the JP Morgan Healthcare Conference. The company aims for $1 billion in revenue by 2030.
Key Events · Corporate Governance and Compliance · AVNS
-
2025 Full-Year Estimates Provided
The company provided net sales guidance of $690-$700 million and adjusted EPS of $0.85-$0.95 for the full year 2025.
-
Strategic Vision for $1 Billion Revenue by 2030
Avanos Medical outlined a path to achieve $1 billion in revenue by 2030, driven by five strategic imperatives including accelerating growth in key segments and synergistic M&A.
-
Tariff Headwinds and Mitigation Plans Detailed
The presentation disclosed an estimated $18 million tariff headwind for 2025 and detailed mitigation plans, including exiting China neonatal syringe production and targeting $15-$20 million in annualized savings by the end of 2026.
-
Business Update Highlights Growth and M&A
The company highlighted its solid organic growth profile, market-leading positions, expanding global sales organization, and an attractive M&A pipeline.
Analysis · AVNS · Industrial Applications And Services
This 8-K filing discloses Avanos Medical's presentation at a major healthcare conference, providing investors with a comprehensive update on its business and financial outlook. The company outlined its 2025 full-year net sales and adjusted EPS estimates, alongside a detailed strategy to achieve $1 billion in revenue by 2030. Key elements include leveraging market-leading positions, expanding global sales, and pursuing M&A opportunities. Importantly, the presentation addressed a significant $18 million tariff headwind for 2025 and detailed mitigation plans, including exiting China neonatal syringe production and implementing cost optimization, which are projected to yield $15-$20 million in annualized savings by the end of 2026. This forward-looking information, coupled with the strategic vision, provides crucial insights into the company's operational and financial trajectory.
How filings like this one have moved
In the 30 days to Sep 15, 2026, 29.9% of the 1678 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.25%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AVNS was trading at $11.40 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $529.2M. The 52-week trading range was $9.30 to $17.69. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.